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Bone marrow angiogenesis can be measured by DCE-MRI. DCE-MRI is an imaging technique that appears
to provide quantitative and biologically relevant information related to tumor vasculature and angio-
genesis, which can inform novel drug efﬁcacy, monitor treatment response and act as an imaging
biomarker to predict treatment outcome and survival in hematological malignant patients. Increased
bone marrow perfusion as reﬂected by higher Peak value can independently predict adverse clinical
outcome in patients with acute myeloid leukemia (AML). In addition, DCE-MRI derived data of bone
marrow in AML patients at remission status provides useful information on clinical outcome of patients
who might have relapse or not. Patients with a higher value for Kep at remission status would have
shorter relapse-free duration and may need to undergo additional therapy. In multiple myeloma, DCE-
MRI data correlate strongly with marrow tissue microvessel density. Studies identify high Amplitude
values as a possible risk factor associated with the development of extra-medullary disease in multiple
myeloma patients; these ﬁndings partly support the hypothesis that bone marrow angiogenesis may play
role in the development of extra-medullary disease in multiple myeloma. DCE-MRI derived-parameters
could serve as a guidance for the selection of optimal management plans, thereby contributing to the
development of “personalized medicine” for patient.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Personalizedmedicine is themajor goal of translational research
in the post-genomic era.1 Numerous biomarkers have been iden-
tiﬁed by genomic or proteomic approach that can reclassify the
disease phenotype and predict clinical outcome.2 However, to
deﬁne a speciﬁc disease phenotype, it is not necessarily depend on
molecular or genomic technologies.
Angiogenesis is one of the factors that correlate with the tumor
aggressiveness and clinical outcome of patients with malignant
solid tumors such asmelanoma,3e6 prostate cancer,7 breast cancer,8
and also in so called “liquid tumors” such as leukemia or lym-
phomas9,10 and multiple myeloma.11e13 Microvessel density (MVD)
is traditional “gold standard” for quantiﬁcation of angiogenesis in
tumor tissue. MVD increased in patients with acute leukemia withNational Taiwan University
., Taipei 10002, Taiwan.
ncology Society.
Society. Production and hosting byactive disease in comparison to healthy controls or patients in
remission. It is also known that various parameters such as age,
karyotype, and performance status are prognostic factors in acute
myeloid leukemia (AML) patients before they receive chemo-
therapy.14,15 However, MVD can be measured only in the limited
area of the bone marrow (BM) biopsy specimen; thus, it cannot be
used to assess the global or in vivo tumor angiogenesis. None of the
functional status of the tumor blood vessel (such as permeability,
elimination rate) could be determined by the above-mentioned
immunohistochemical methods of MVD.16e19
On the other hand, once patients achieve complete remission
(CR) after standardized treatment, an ideal prognostic predictor
that should be rapidly and easilymeasurable and reproducible to be
adopted into routine clinical practice is still absent.20 Although the
likelihood of relapse declines sharply to less than 10% once CR
persists for 3 years,21 the challenge remains of maintaining
remission. The ability to detect patients at high risk of relapse may
help in the design of therapeutic strategies to improve the duration
of remission. Therefore, an accurate assessment of bone marrow
microenvironment in these patients in whom CR is achieved isElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
T. Ting-Fang Shih / Journal of Cancer Research and Practice 3 (2016) 97e10398essential to detect early relapse and evaluate treatment
effectiveness.
Because the BM microenvironment should change considerably
after the initial induction chemotherapy,22 it is reasonable that the
data collected at CR status would be more useful than pretreatment
data to predict the survival outcome of these patients. For example,
ﬁndings in a recent study suggested that neutrophil count and
platelet count at the time of CR can serve as independent factors for
prediction of relapse-free survival (RFS).23 Another study described
that the cytogenetic analysis performed at the time of CR is a pre-
dictor of overall survival (OS), RFS, and relapse rate in AML
patients.24
The aggressiveness of angiogenesis is not only well known in
acute leukemia, but also noted in multiple myeloma. Multiple
myeloma (MM) is a malignant plasma cell proliferation typically
found in BM.25 Although MM cells (MCs) depend on the BM
microenvironment to provide the signals essential for their growth
and survival, in a fraction of patients MCs acquire the ability to
proliferate in sites outside the BM. Such occurrences appear as
extramedullary disease (EMD), indicating that MCs have become
independent of the BMmicroenvironment.25 The exact mechanism
underlying the development of EMD in MM patients is not clear.
One hypothesis suggests an alteration in the interaction between
MCs and the BM microenvironment.26,27 Therefore, the BM
“angiogenesis” might also play a major role in not only promoting
the growth and survival of MCs but also the disease progression
itself.26e28 The interaction between MCs and BM endothelial cells
upregulates a number of angiogenic cytokines, such as vascular
endothelial growth factor or matrix metalloproteinases. Such cy-
tokines further stimulate BM angiogenesis and myeloma progres-
sion,29,30 as well as possible extramedullary dissemination.28
New technologies for cancer image with functional assessment
are now possible in vivo by Doppler sonography, dynamic contrast-
enhanced (DCE)-MRI, DCE computed tomography (CT), and
ﬂuorodeoxyglucose-18 positron emission tomography (PET).31e33
DCE-MRI is a noninvasive and quantitative method of investi-
gating microvascular structure and function by tracking the phar-
macokinetics of injected low-molecular-weight contrast agents as
they pass through the tumor vasculature.34 This technique provides
a direct quantiﬁcation of blood vessel density, vascular ﬂow, and
permeability.35e37 Up to date, DCE-MRI is one of the most widely
used noninvasive methods of measuring the perfusion and
permeability of a biological tissue in the body, such as vertebral
BM.38 In addition, functional imaging biomarkers may be used to
assess treatment response earlier.39 This modality is being
increasingly used in many oncological studies, including those of
patients with hematologic cancers,14,15,40e42 to characterize tumor
angiogenesis and invasiveness and to monitor the treatment
response.31,32,43 There have been increasing attempts to use this
approach to assess spatial and temporal heterogeneity in tumor
angiogenesis and to predict tumor biologic aggressiveness and
treatment response in not only solid tumors,44e47 but also in leu-
kemia/lymphoma, multiple myeloma,48 and myelodysplastic
syndrome.49
2. Basis and methodology of DCE-MRI
DCE-MRI images are performed by using injecting low-
molecular-weight gadolinium chelated contrast agent with a con-
stant, stable rate.50 The contrast agent is carried by blood ﬂow into
the tissue, causing increased signal intensity (SI) of the T1-
weighted images due to the shortening of relaxation time of the
tissue.51 Within the tissue, the contrast agent passes from the ar-
teries to the capillaries, and then permeates to the extravascular
extracellular space (EES). The rate of contrast agent extravasation toEES in the tumor tissue is determined by vessel leaky and blood
ﬂow. Thus, the signal counted on DCE-MRI represents a combina-
tion of permeability and tissue perfusion. DCE-MRI is sensitive to
alterations in vascular permeability, extracellular space, and blood
ﬂow. To ideally record the signal change in the supplying blood
vessel and within the tumor, a regular injection rate of the contrast
agent captured with proper temporal resolution according to the
ﬂow rate of the investigated tissue is recommended.52
This signal enhancement of bone marrow perfusion can be
quantiﬁed either with a semi-quantitative or quantitative analysis.
The semi-quantitative analysis is based on the calculation of heu-
ristic parameters that can be easily extracted from SI curves. In
contrast, the quantitative analysis needs model-based curve ﬁtting
algorithms using a bi-compartmental model as well as arterial
input function. The parameters from both analysis methods have
been shown to present correlation with bone marrow angiogenesis
and MVD by immune-histochemical stain from biopsy tissue
counting.53 Our research protocols for the use of DCE-MRI of BM
perfusion and angiogenesis measurement have been described
previously.54,55 In brief, DCE-MRI was performed at the midsection
of vertebral bodies from T11 to sacrum, and the values of signal
from L2 to L4 were measured by a radiologist and plotted as a
timeeSI curve. The timeeSI curve was then ﬁtted by the Mathe-
matica (v 6.1) software (Wolfram Research, Champaign, IL) using a
nonlinear curve-ﬁtting function. The baseline SI (SI base) on a
timeeSI curve was deﬁned as the mean SI for the ﬁrst ﬁve images,
and themaximum SI (SI max) was deﬁned as themaximumvalue of
the ﬁrst rapidly rising part of the curve. We usually set the total
duration of DCE-MRI examination at 600 s to track the uptake ki-
netics of contrast agents. The contrast enhancement rise time (T
rise) was deﬁned as the time between SI base and SI max. The two
semi-quantitative parameters, Peak and Slope, were calculated as
(SI max SI base)/SI base and (SI max SI base)/T rise, respectively.
On the other hand, the angiogenesis parameters based on DCE-
MRI could be described by three model quantitative parameters,
Amp, Kep, and Kel, calculated using the bi-compartmental
model.54,55 Data for each patient were represented as the average
for the parameters of vertebral bodies from L2 to L4. Among these
semi-quantitative and quantitative parameters, Peak indicates the
contrast material in the intra- and extra-vascular interstitial spaces,
representing tissue perfusion; Slope predominantly indicates the
contrast agent in the intravascular space, which is determined by
tissue vascularization and perfusion as well as capillary perme-
ability; Amp is similar to Slope but provides better quantiﬁcation of
vascularity. The efﬂux rate constant is represented as Kep, which
indicates the permeability. The Kep parameter is a rate transfer
coefﬁcient. More details about the measurement methods were
listed as below:3. Semi-quantitative analysis
Regarding the semi-quantitative analysis, different parameters
that characterize the shape of the normalized SI time curve can be
extracted: (1) area under curve (AUC): expresses the amount of
enhancement over a deﬁned period of time (usually from starting
increment of the time intensity curve to 60 or 90 s); (2) maximum
of SI or Peak enhancement ratio (SI maximum  SI baseline/SI
baseline) of the enhancing curve; (3) wash-in Slope: determines
the velocity of enhancement. It is calculated as the maximum
change in enhancement per unit time, usually from 20% to 80%
range of the slope of increment curve; and (4) mean transit time
(MTT): represents the mean time for blood to perfuse a region of
tissue and is affected by the blood volume and blood ﬂow in the
region under analysis.
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to calculate without the need of modeling. However, these pa-
rameters are highly affected by the factor of the acquisition sys-
tems, contrast media volume and injection rate, because the true
concentration of contrast agent in the tissues is not estimated. Thus,
differences in temporal resolution and injection rates can easily
change the shape and amplitude of SI curves, making comparison
and quantiﬁcation difﬁcult.56,57 Moreover, these descriptive pa-
rameters provide no physiologic meaning into the behavior of the
tumor vessels.4. Quantitative analysis
The quantitative analysis is based on modeling the concentra-
tion change of the contrast agent using pharmacokinetic modeling
techniques.58 An initial conversion of SI to concentration values is
needed. Concentration vs time curves are then ﬁtted using a bi-
compartmental PK model (vessels and EES) with single vascular
input (usually aorta or other). The following parameters can be
derived from a mathematical model59: (1) Ktrans (volume transfer
constant): determines the inﬂux of the contrast agent from the
intravascular space to the EES. It predominantly represents the
vascular permeability in a permeability-limited (high ﬂow) situa-
tion, but represents the blood ﬂow into the tissue in a ﬂow-limited
(high permeability) situation; (2) Kep (reverse reﬂux rate con-
stant): expresses the return process of the contrast agent from the
EES to the intravascular space; and (3) Ve (volume fraction of EES):
an indirect measure representing the cellular density of the tissue.
In the micro-environment of bone marrow, the above mentioned
parameters are more related to low ﬂow status, because the blood
perfusion rate of marrow is rather slow as compared with other
organ/systems. Those data represents the blood ﬂow into the tissue
in a ﬂow-limited situation.
These parameters require additional calculations to generate
parametric maps obtained after a pixel-by-pixel curve ﬁtting pro-
cess of the region under analysis. Thus, they are more computa-
tionally technical to obtain than the semi-quantitative ones. After
generating parametric maps, the mean or median values within
region of interests (ROI) are usually calculated to represent
microvasculature, but histogram analysis60 or heterogeneity in
parametric maps61e63 may also provide additional information. For
optimum parameter quantiﬁcation, a moderate temporal resolu-
tion is required to record initial rapid uprising of the SI curve
immediately after the contrast agent administration.64 The accu-
racy of these parameters is inﬂuenced by curve ﬁtting algo-
rithms65,66 and magnitude of motion artifacts.67 Luckily, the
environment of BM would not count on motion artifact.5. Model selection
Kety68 ﬁrst described the ﬂow-limited tracer uptake in tissue,
and since then several pharmacokinetic models have been pro-
posed by Tofts et al.,69 Brix et al.70 All these models used single
source of arterial input function. However, for BM parenchymal
disease, which are supplied by small arteriole such as segmental
artery directly arising from aorta, a single-input, bi-compartment
PK model by Brix and Tofts is often used to obtain.
The choice of contrast agent molecular properties71 and the
temporal resolution of the acquisition have a clear inﬂuence on the
parameters. To standardize calculations, the acquisition should
have proper temporal resolution (about 5 s each image set, during
at least 5 min or 300 s), and voxel-wise statistical analysis is
suggested.6. Clinical application of DCE-MRI
Increased bone marrow MVD was reported in patients with
AML, but its association with patients' survival is unclear and
inconclusive,18,72,73 probably because the MVD detected by con-
ventional immunocytochemical technique is unable to assess the
global and dynamic angiogenesis of the bone marrow. Vascularity
within a tumor can be spatially or temporally heterogeneous; and
tumor vessels are much more permeable than are normal blood
vessels. Thus, assessment of angiogenesis in the BM by traditional
MVD poses special challenges.74e76
Dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) can provide global and functional imaging of tumor angio-
genesis. A previous research,37 demonstrated that the rate of
vertebral marrow perfusion decreased signiﬁcantly in subjects
older than 50 years, but it decreased in a relatively slow speed.
However, the differences of BM perfusion between patients with
AML and age- and sex-matched healthy subjects were drastic.22
The patients with AML had much higher Peak values (as the key
parameter) than did the age- and sex-matched controls (almost
4.8-fold difference), and the distribution had no overlap between
these 2 groups. Thus, we can postulate that, although the age factor
has inﬂuence on the Peak of the bone marrow, it is minor and can
be overridden by the great effect of tumor angiogenesis.
Bone marrow DCE-MRI performed at diagnosis and complete
remission of the acute myeloid leukemia (AML) patients, those
multi-parametric data from DCE-MRI correlated signiﬁcantly with
treatment outcome. Three distinct parameters: peak enhancement
ratio (Peak) to indicate tissue blood perfusion; amplitude (Amp) to
reﬂect vascularity; and volume transfer constant (Ktrans) to indi-
cate vascular permeability. The Peak and Amp decreased signiﬁ-
cantly at remission status after induction chemotherapy as
compared to their initial status (Figs. 1 and 2). Patients with higher
Peak or Amp at initial diagnosis (before any intervention) had
shorter overall survival and disease-free survival than others. Cox
multivariate analysis identiﬁed higher Peak value (hazard ratio,
9.181; 95% conﬁdence interval, 1.740e48.437; p ¼ 0.009) as an in-
dependent predictor for overall survival in addition to unfavorable
karyotype and old age. These ﬁndings provide evidence that
increased BM angiogenesis measured by DCE-MRI can predict
adverse clinical outcome in AML patients and may help to select
high-risk phenotype AML patients for tailored antiangiogenic
therapy and to monitor treatment response.
DCE-MRI may be a better alternative method than MVD in bone
marrow biopsy specimens because it is non-invasive and can
evaluate much bigger bone volumes, thus better representing the
overall disease burden. This has prompted novel antiangiogenic
approaches in AML.77e80 The current study's ﬁnding that DCE-MRI
assessment of patients with AML with increased bone marrow
angiogenesis can predict poor clinical outcome also indicates that
anti-angiogenesis treatment may be beneﬁcial for these patients.
More importantly, DCE-MRI can provide noninvasive, conve-
nient, and reproducible serial evaluations of global bone marrow
angiogenesis diagnostics with only 600 s of scanning time and
preparation for whole scanning only less than 20 min. This is more
practical than repeated bone marrow biopsies and MVD studies. In
short, DCE-MRE play an important role to help physicians both
identify the most appropriate patients for antiangiogenic therapies
for the best treatment results and to monitor the response to
treatment. Moreover, the ﬁnding that patients receiving bone
marrow transplantation survive longer than those without in the
group with higher Peak value implies that bone marrow trans-
plantation may be a therapeutic option for those with higher bone
marrow angiogenesis. Further studies in more patients are needed
to clarify this point. According to the large-scale prospective study
Fig. 1. a: Timeeintensity curve of a 55 year-old female detected on day 0; the highest spot of the curve was noted as signal of 53. b: Peak derived color map for bone marrow of
lumbar spine detected on day 0. The regions of interest (ROIs) were placed on 2nd, 3rd and 4th vertebrae. The average of the three vertebrae showed Peak value as 3.0. c: Kep
derived color map for bone marrow of lumbar spine detected on day 0. The regions of interest (ROIs) were placed on 2nd, 3rd and 4th vertebrae. The average of the three vertebrae
showed Kep value as 13.1.
Fig. 2. a: Timeeintensity curve of a 55 year-old female detected on day 7th; the highest spot of the curve was noted as signal of 36. b: Peak derived color map for bone marrow of
lumbar spine detected on day 7th. The regions of interest (ROIs) were placed on 2nd, 3rd and 4th vertebrae. The average of the three vertebrae showed Peak value as 2.0. The Peak
value had dramatic decrease on day 7 after induction chemotherapy. c: Kep derived color map for bone marrow of lumbar spine detected on day 7. The regions of interest (ROIs)
were placed on 2nd, 3rd and 4th vertebrae. The average of the three vertebrae showed Kep value as 3.7. The Kep had dramatic decrease after induction chemotherapy.
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angiogenesis in patients with AML is a possible and convenient
method achievable. The pretreatment Peak, reﬂecting bone
marrow perfusion, and Amp, reﬂecting vascularity, of functional
bone marrow angiogenesis MRI can predict overall survival and
disease free survival of patients with newly diagnosed AML. More
intriguingly, higher Peak value was an independent predictor for
poor overall survival. These ﬁndings suggest that functional MRI of
BM angiogenesis is a useful biomarker to predict clinical outcome
of patients with AML, and tumor angiogenesis may play an
important role in the pathogenesis of AML.19,77
Another study also showed that a decreasing peak enhancement
ratio after induction chemotherapy was associated with a higher
chance of achieving complete remission (CR), better overall survival
(OS), and also disease-free survival (DFS).22 On the other way, the
research has demonstrated that DCE-MR imaging parameters in
AML patients with a CR status may be an indicator of survival and
outcome and serve as an imaging biomarker for selecting risk-
adapted treatment.81 All DCE MR imaging parameters (peak,
slope, amplitude, Kep, and Kel) had a signiﬁcant association with
OS; however, only Kep was signiﬁcantly related to RFS in the uni-
variate analysis. Furthermore, Kep was an independent prognostic
factor of OS and RFS in the multivariate.It is noteworthy that, even with low tumor burden in these
patients following CR, peak value at CR status is still a useful indi-
cator for OS, both in the whole cohort, andmore importantly, in the
intermediate-risk subgroup. Slope is mainly determined by tissue
vascularization and perfusion, but capillary permeability may also
play an important role.82e86 A previous study40 showed that high
values for amplitude at initial DCE MRI is a poor risk factor for
disease-free and overall survival in AML patients. In addition, a high
value for amplitude at DCE MRI in patients in CR is also associated
with shorter OS. Kep, a rate transfer coefﬁcient, represents contrast
exchange between blood plasma and extravascular extracellular
space.55 It was strongly inﬂuenced by permeability and also posi-
tively correlated with the perfusion and plasma volume but nega-
tively associated with the interstitial volume.84 According to the
hypothesis,87 antiangiogenic agents can normalize abnormal tumor
vasculature, resulting in more efﬁcient delivery of drugs and oxy-
gen to targeted cancer cells. Under this assumption, when patients
achieve CR, bone marrow vessels and their endothelium should be
normalized with reduced vessel wall permeability, and bone
marrow cells should return to normal karyotype. Failure of this
repair process would result in persistent high vascular permeability
and a high value for Kep. Therefore, increased values for Kep in
patients with CR status who undergo DCEMR imagingmay indicate
T. Ting-Fang Shih / Journal of Cancer Research and Practice 3 (2016) 97e103 101a high risk of relapse and shorter OS and RFS. The high permeability
of the bone marrow may also be associated with high vascular
endothelial growth factor protein expression.87,88 A high level of
vascular endothelial growth factor expression in tumor cells is
associated with neovascularization, tumor aggressiveness, and
poor prognosis in AML patients.24 The result implies that Kep at
remission status, representing the interaction of capillary endo-
thelial permeability, interstitial or intraosseous pressure, and
diffusion of molecules between the capillary bed and the interstitial
space,89 may be a suitable marker for current angiogenesis.
In multiple myeloma (MM) patients, the angiogenesis parame-
ters generated from DCE-MRI of vertebral BM reportedly also
correlate strongly with histological grade of inﬁltration, osteolytic
bone involvement, microvessel density (MVD), and serum markers
of disease activity.32,48 Extramedullary Disease (EMD) in patients
with MMwas deﬁned as the presence of MCs outside BM, in one of
the following forms: soft-tissue mass spreading from the bone
(periosseous plasmacytoma), MCs arising in extraosseous organs
(extraosseous plasmacytoma), malignant effusion, or plasma cell
leukemia. The presence of EMD was diagnosed in most cases by
MRI or computed tomography, which were conducted whenever
EMD was suspected from clinical, laboratory, or radiographic
ﬁndings. However, no data of prior study were available on the
correlation between degree of BM angiogenesis and the develop-
ment of EMD inMMpatients. Huang et al. examined the correlation
between angiogenesis parameters generated from DCE-MRI of
vertebral bodies, together with MVD in BM (obtained from the
posterior iliac crest), with the manifestation of EMD in patients
with MM.90 The mean MVD with signiﬁcant differences being
found for patients in different subgroups. Patients with extra-
medullary disease (EMD) had a higher mean MVD of 20.3 (95%
conﬁdence interval [CI: 15.3e25.2]), patients in the non-EMD group
had a lower mean MVD of 3.2 (95% CI: 1.4e5.0); but patients with
progression disease had ameanMVD of 15.7 (95% CI: 9.9e21.5). The
timeesignal intensity (SI) curve shown in DCE-MRI correlated
strongly with tissue MVD, where a high peak and steep slope were
associated with high MVD. By contrast, a lower peak and gentler
slopewere associatedwith lowerMVD.Moderate correlations were
found between MVD and the two semi-quantitative parameters
Peak and Slope (both p < 0.001). The quantitative parameters, Amp
and Kel, but not Kep, were also moderately correlated with MVD.
Other salient characteristics signiﬁcantly correlated with MVD
were beta2-microglobulin, C-reactive protein, and percentage of
MCs in BM. Further multiple linear regression analysis showed that
only Amp and percentage of MCs in BM were independently
correlated with MVD. In addition, multiple logistic regression
model showed that Amp was the only signiﬁcant factor associated
with EMD (OR ¼ 6.33). The accumulative incidence for develop-
ment of EMD over time was signiﬁcantly higher for patients with
high Amp (>0.08) than for patients with low Amp (<0.08). Addi-
tional covariates were identiﬁed by univariate analysis as being
signiﬁcantly associated with the development of EMD, including
light chain isotype, high Kel (>0.10), and high calcium (>2.4 mmol/
l). However, multivariate analysis using the Cox regression model
did not conﬁrm that any of these factors was independently sig-
niﬁcant. This study demonstrates a possible correlation between
the angiogenesis parameter Amp (generated from DCE-MRI of
vertebral BM) and EMD in patients with MM. These results iden-
tiﬁed high Amp values (>0.08) as a possible risk factor associated
with the development of EMD in MM patients; high Amp values
indicate high tissue vascularity and permeability. This ﬁnding
partly supports the hypothesis that BM angiogenesis may play role
in the development of EMD in MM.91 Thus, for MM patients,
quantitative analysis is necessary using DCE-MRI data and angio-
genesis and blood-vessel permeability based microcirculationvariables. However, a fuller understanding of what these various
measurements imply is necessary before such assessments can be
incorporated into routine clinical practice.
Another recent study also concluded that presence of EMD at
diagnosis, rather than any treatment modalities ever used, was the
only signiﬁcant predictor of extramedullary recurrence. This
ﬁnding suggests that the development of EMD, even during treat-
ment, may possibly reﬂect different tumor biology.92 One issue
raised about the MVD is the histological specimen was obtained
usually from the posterior iliac crest and not the vertebral column.
This is of some concern, because MM may grow in a patchy rather
than diffuse pattern; therefore, the degree of inﬁltration of the BM
by MCs cannot be expected to be equal throughout the skeleton.
However, controversy still surrounds the possible correlation
between parameters of DCE-MRI and angiogenesis genes in MM
patients.30 Authors concluded that90 among MM patients, the
angiogenesis parameter Amp was strongly correlated with the
tissue MVD of BM obtained from the posterior iliac crest. This
ﬁnding possibly reﬂects not only the tissue-speciﬁc vascularity, but
also the vascular permeability in a more sizable area than the MVD
of BM. As a result, Amp rather than MVD may correlate with the
development of EMD among MM patients. Thus, high Amp might
be a risk factor that could help identify MM patients with the po-
tential to develop EMD. When compared with patients without
EMD, patients with EMD displayed signiﬁcantly greater inﬁltration
of MCs in BM and higher levels of angiogenesis parameter “Amp”.
Multiple logistic regression model showed that Amp was the only
signiﬁcant factor associated with EMD.
7. Limitation and future direction
Dynamic contrast-enhanced MR imaging is a reproducible
technique. According to many previous studies, the reproducibility
of Peak, Amp, Kel and Ktrans is good. This suggests that in a well-
conducted study, a change of Peak or Ktrans value is likely to
indicate a signiﬁcant biomarker of therapeutic prognosis. However,
current DCE-MRI technique lacks standardization across multiple
MR platforms and institutions, making it difﬁcult to implement the
technique in a multicenter setting. Besides, there is a need to
establish clear thresholds for a signiﬁcant response when using
quantitative DCE-MR imaging parameters for assessment of ther-
apy response.
8. Conclusions
Bone marrow angiogenesis can be measured by DCE-MRI. DCE-
MRI may provide dynamic and functional tumor angiogenesis and
may help identify high-risk patients for tailored anti-antigenic
therapy and monitoring treatment response. Increased bone
marrow perfusion as reﬂected by higher Peak value can indepen-
dently predict adverse clinical outcome in patients with AML. All
DCE-MR parameters were signiﬁcantly associated with overall
survival. In addition, DCE-MRI data of bonemarrow in AML patients
at remission status can provide useful information on clinical
outcome of patients who achieve CR. High Kep is an independent
factor of overall and relapse free survival in these patients inwhom
CR was achieved. Patients with a higher value for Kep at CR would
have shorter relapse-free duration and may need to undergo
additional therapy.
In multiple myeloma, DCE-MRI correlated strongly with tissue
MVD, where a high peak and steep slope were associated with high
MVD. Study identiﬁed high Amp values as a possible risk factor
associated with the development of extra-medullary disease inMM
patients; high Amp values indicate high tissue vascularity and
permeability. This ﬁnding partly supports the hypothesis that BM
T. Ting-Fang Shih / Journal of Cancer Research and Practice 3 (2016) 97e103102angiogenesis may play important role in the development of EMD
in MM.
DCE-MRI is an imaging technique that appears to provide
quantitative and biologically relevant information related to tumor
vasculature and angiogenesis, which can inform novel drug efﬁ-
cacy, monitor treatment response and act as an imaging biomarker
to predict treatment outcome and survival in hematological ma-
lignant patients. These parameters could serve as a guide for the
selection of optimal management plans, thereby contributing to the
development of “personalized medicine” for patient.
A 55 year old female was diagnosed as acute myeloid leukemia,
M0, NPM1 (), FLT3/ITD (), RUNX1 (þ), CEBPA (). She suffered
from intermittent fever and cough for about 1 week since middle of
2015 Feb. Mild dyspnea, rhinorrhea, chillness and abdominal
discomfort were also noted few days later. She denied night
sweating or weight loss. On Feb 20th, she went to emergency
department, where blast cell in peripheral blood was noted with
increased count (WBC: 19370, Blast: 71%). Bone marrow study on
2015/Feb 24th, which proved the diagnosis of AML(M0); Flow
cytometry revealed: Acute myeloid leukemia, M0 (FAB); the blasts
express CD34, CD38, partial CD33, dim CD13, but negative for PO
staining or MPO. Cytogenetics: 47XXþ11[5/6], 46XX [1/6]; Muta-
tion: NPM1 (), FLT3/ITD (), RUNX1 (þ), CEBPA (). Based on the
diagnosis conﬁrmed, she received dynamic contrast magnetic
resonance study (DCE-MRI) before induction chemotherapy (as day
0). After the MR study, induction chemotherapy started with I2A5
on 2015/March 10th. There was no speciﬁc discomfort. Grade IV
neutropenia was noted on Day 4. Second DCE-MRI was performed
at the end of induction chemotherapy (as day 7th).
Multi-parametric DCE-MR data was illustrated as below:
Fig. 1aec were the time intensity curve (a), peak (b) and Kep (c)
acquired from patient before chemotherapy (day 0). Fig. 2aec were
the time intensity curve (a), peak (b) and Kep (c) were acquired
from patient after complete the induction chemotherapy (as day 7).
The difference was signiﬁcant and well demonstrated.
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